Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation
Teruo Inoue, MD, FACC*,
,*,
Toshihiko Uchida, MD
,
Masashi Sakuma, MD
,
Yoshitaka Imoto
,
Yasushi Ozeki, PhD
,
Yukio Ozaki, MD
,
Yutaka Hikichi, MD* and
Koichi Node, MD*
* Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Japan
Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Koshigaya, Japan
Yufu Itonaga Company, Tokyo, Japan
Department of Laboratory Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Tamaho, Japan

View larger version (21K):
[in a new window]
|
Figure 2 Correlation between angiographic late lumen loss and relative changes in platelet P-selectin (left panel) and neutrophil CD11b (right panel) at 48 h after coronary stenting. Open circles = cilostazol group (n = 34); solid circles = ticlopidine group (n = 32).
|
|

View larger version (36K):
[in a new window]
|
Figure 3 Cilostazol's direct action for Mac-1 (CD11b). Cilostazol inhibited an expression of Mac-1 on surface of neutrophils in vitro in a dose-dependent manner, compared with the control (+dimethyl sulfoxide [DMSO] +formyl-methyonyl leucyl phenylalanine [FMLP]). *p < 0.05. **p < 0.01.
|
|
Copyright © 2004 by the American College of Cardiology Foundation.